# Transcenta

Source: https://onco.cc/companies/transcenta/  
OnCo record `transcenta` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Transcenta is a Suzhou antibody company whose Claudin 18.2 antibody osemitamab (TST001) is being tested with nivolumab and chemotherapy as first-line treatment for stomach cancer.

## Summary

Transcenta, listed in Hong Kong, develops antibodies with its own continuous-manufacturing platform. Osemitamab (TST001), a high-affinity Claudin 18.2 antibody with enhanced antibody-dependent cytotoxicity, has shown activity with nivolumab and chemotherapy in first-line gastric and gastro-oesophageal junction cancer and has orphan designations for gastric and pancreatic cancer. TST003 targets Gremlin1 in solid tumours and TST005 is a PD-L1 and TGF-beta bifunctional antibody.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Transcenta Holding; Suzhou Transcenta Therapeutics; 创胜集团; HKEX:6628
- Tags: drug-maker
- HQ: Suzhou
- Type: biotech
- Website: https://www.transcenta.com/
- Ticker: HKEX:6628

## Sources

- Official website: https://www.transcenta.com/

## Connected records

- drugs: [TST001](https://onco.cc/drugs/tst001/), [TST003](https://onco.cc/drugs/tst003/)
- trials: [A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors](https://onco.cc/trials/nct05731271/), [A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04396821/), [A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04495296/)

---
JSON: https://onco.cc/api/v1/entities/transcenta.json